KBC Group’s Bicycle Therapeutics BCYC Stock Holding History

KBC Group’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,750	Closed	-$156K	–	1289
2021 Q3	$156K	Sell	3,750 -3,750	-50%	-$131K	﹤0.01%	1105
2021 Q2	$228K	Hold	7,500	–	–	﹤0.01%	1155
2021 Q1	$224K	Buy	+7,500	New	+$193K	﹤0.01%	1165

Other funds holding BCYC

RCI

Ridgeback Capital Investments Miami Beach, Florida $560K AUM

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

KBC Group's BCYC Position: Q4 2021 in Review

KBC Group sold out of Bicycle Therapeutics (BCYC) in Q4 2021, closing a stake of 3,750 shares — an estimated $156K sold.

KBC Group first reported a position in BCYC in Q1 2021 and held it in 3 quarters. The position peaked at $228K in Q2 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2021.

KBC Group reported no remaining Bicycle Therapeutics position as of Q4 2021 after selling out during the quarter.
KBC Group sold 3,750 Bicycle Therapeutics shares in Q4 2021, an estimated $156K.
KBC Group first reported a position in Bicycle Therapeutics in Q1 2021 and held it in 3 quarters.
KBC Group's Bicycle Therapeutics position peaked at $228K in Q2 2021.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.